Press Releases

YEAR
Toggle Summary Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Nov. 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner,
View HTML
Toggle Summary Nabriva Announces Availability of XENLETA® (lefamulin) in a 10-Count Oral Pack
10-count oral pack – or ‘X’ pack allows for improved access and the opportunity to further expand retail availability DUBLIN, Ireland and FORT WASHINGTON, Pa. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization
View HTML
Toggle Summary Nabriva Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
-Revenues of $8.9 million increased 8% sequentially versus Q2 2021- -SIVEXTRO Net Sales & Prescriptions both grew 14% sequentially versus Q2 2021- -Cash runway extended to substantially through Q2 2022- -Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland , Nov.
View HTML
Toggle Summary Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder ,
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Nov. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted a non-statutory stock option
View HTML
Toggle Summary Nabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021
DUBLIN, Ireland , Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial
View HTML
Toggle Summary Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today, announced data presentation at
View HTML
Toggle Summary Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today published the first data to
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted a non-statutory stock option
View HTML
Toggle Summary Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the appointment of Dr.
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com